Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

被引:224
作者
Wu, Annie A. [1 ]
Drake, Virginia [2 ]
Huang, Huai-Shiuan [3 ]
Chiu, ShihChi [3 ]
Zheng, Lei [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[3] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
关键词
immunosuppression; immunotherapy; immunosuppressive factors; T cells; tumor microenvironment; GROWTH-FACTOR-BETA; BCL-X-L; INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; MYELOID SUPPRESSOR-CELLS; SMALL-MOLECULE INHIBITOR; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; DOWN-REGULATION; IMMUNE-RESPONSES; GENE-EXPRESSION;
D O I
10.1080/2162402X.2015.1016700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has become evident that tumor-induced immunosuppressive factors in the tumor microenvironment play a major role in suppressing normal functions of effector T cells. These factors serve as hurdles that limit the therapeutic potential of cancer immunotherapies. This review focuses on illustrating the molecular mechanisms of immunosuppression in the tumor microenvironment, including evasion of T-cell recognition, interference with T-cell trafficking, metabolism, and functions, induction of resistance to T-cell killing, and apoptosis of T cells. A better understanding of these mechanisms may help in the development of strategies to enhance the effectiveness of cancer immunotherapies.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 276 条
[1]   Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy [J].
Ahmed, Mahiuddin ;
Cheung, Nai-Kong V. .
FEBS LETTERS, 2014, 588 (02) :288-297
[2]   The Inflammatory Chemokine CCL5 and Cancer Progression [J].
Aldinucci, Donatella ;
Colombatti, Alfonso .
MEDIATORS OF INFLAMMATION, 2014, 2014
[3]   Suppressors of cytokine signalling (SOCS) in the immune system [J].
Alexander, WS .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :410-416
[4]   Survivin, versatile modulation of cell division and apoptosis in cancer [J].
Altieri, DC .
ONCOGENE, 2003, 22 (53) :8581-8589
[5]   Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies [J].
Ascierto, Paolo A. ;
Simeone, Ester ;
Sznol, Mario ;
Fu, Yang-Xin ;
Melero, Ignacio .
SEMINARS IN ONCOLOGY, 2010, 37 (05) :508-516
[6]   Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer [J].
Astigiano, S ;
Morandi, B ;
Costa, R ;
Mastracci, L ;
D'Agostino, A ;
Ratto, GB ;
Melioli, G ;
Frumento, G .
NEOPLASIA, 2005, 7 (04) :390-396
[7]   Unraveling galectin-1 as a novel therapeutic target for cancer [J].
Astorgues-Xerri, Lucile ;
Riveiro, Maria E. ;
Tijeras-Raballand, Annemilai ;
Serova, Maria ;
Neuzillet, Cindy ;
Albert, Sebastien ;
Raymond, Eric ;
Faivre, Sandrine .
CANCER TREATMENT REVIEWS, 2014, 40 (02) :307-319
[8]  
Aubrey M, 2003, GLYCANS CELL INTERAC
[9]   Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck [J].
Avradopoulos, K ;
Mehta, S ;
Blackinton, D ;
Wanebo, HJ .
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (02) :184-190
[10]   Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes [J].
Bai, XF ;
Liu, JQ ;
Li, O ;
Zheng, P ;
Liu, Y .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (10) :1487-1496